Relationship between serum SDC4 and CatS levels and ventricular remodeling and prognosis in patients with chronic heart failure
Time：2022-07-21 Source：
参考文献(References)：
[1]
中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会.心脏再同步治疗慢性心力衰竭的中国专家共识(2021年修订版)[J].中华心律失常学杂志，2021,25(6):465-478.DOI:10.3760/cma.j.cn113859-20210901-00177.Chinese
Society of Pacing and Electrophysiology,Chinese Society of
Arrhythmias.Chinese expert consensus on the cardiac resynchronization
therapy in patients with chronic heart failure (update 2021)[J].Chin J
Cardiac
Arrhyth,2021,25(6):465-478.DOI:10.3760/cma.j.cn113859-20210901-00177.
[2]
中国医疗保健国际交流促进会循证医学分会，海峡两岸医药卫生交流协会老年医学专业委员会.心力衰竭生物标志物中国专家共识[J].中华检验医学杂志，2020,43(2):130-141.DOI:10.3760/cma.j.issn.1009-9158.2020.02.007.Evidence
Based Medicine Committee Affiliated to China International Exchange and
Promotion Association for Medical and Healthcare,Committee Geriatric
Medicine Affiliated to Cross-straits Medicine Exchange
Association.Chinese expert consensus on biomarkers for heart
failure[J].Chin J Lab
Med,2020,43(2):130-141.DOI:10.3760/cma.j.issn.1009-9158.2020.02.007.
[3]
Tsutsui H,Ide T,Ito H,et al.JCS/JHFS 2021 guideline focused update on
diagnosis and treatment of acute and chronic heart failure[J].J Card
Fail,2021,27(12):1404-1444.DOI:10.1016/j.cardfail.2021.04.023.
[4]
Shaik F,Balderstone MJM,Arokiasamy S,et al.Roles of Syndecan-4 in
cardiac injury and repair[J].Int J Biochem Cell
Biol,2022,146:106196.DOI:10.1016/j.biocel.2022.106196.
[5]
Qiu Y,Buffonge S,Ramnath R,et al.Endothelial glycocalyx is damaged in
diabetic cardiomyopathy:angiopoietin 1 restores glycocalyx and improves
diastolic function in
mice[J].Diabetologia,2022,65(5):879-894.DOI:10.1007/s00125-022-05650-4.
[6]
Soond SM,Savvateeva LV,Makarov VA,et al.Cathepsin S cleaves BAX as a
novel and therapeutically important regulatory mechanism for
apoptosis[J].Pharmaceutics,2021,13(3):339.DOI:10.3390/pharmaceutics13030339.
[7]
马婷婷，邱晓平，张立新.糖尿病合并冠心病患者血浆组织蛋白酶S和血小板反应蛋白-1浓度与心力衰竭的关系[J].岭南心血管病杂志，2020,26(1):48-51.DOI:10.3969/j.issn.1007-9688.2020.01.12.Ma
TT,Qiu XP,Zhang LX.Correlation between plasma concentrations of
cathepsin S,thrombospondin-1 and heart failure in patients with diabetes
mellitus complicated with coronary heart disease[J].South China Journal
of Cardiovascular
Diseases,2020,26(1):48-51.DOI:10.3969/j.issn.1007-9688.2020.01.12.
[8]
中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.慢性心力衰竭基层诊疗指南(2019年)[J].中华全科医师杂志，2019,18(10):936-947.DOI:10.3760/cma.j.issn.1671-7368.2019.10.008.Chinese
Medical Association,Chinese Medical Journals Publishing House,Chinese
Society of General Practice,et al.Guideline for primary care of chronic
heart failure(2019)[J].Chin J Gen
Pract,2019,18(10):936-947.DOI:10.3760/cma.j.issn.1671-7368.2019.10.008.
[9]
Lang RM,Bierig M,Devereux RB,et al.Recommendations for chamber
quantification:a report from the American Society of Echocardiography's
Guidelines and Standards Committee and the Chamber Quantification
Writing Group,developed in conjunction with the European Association of
Echocardiography,a branch of the European Society of Cardiology[J].J Am
Soc Echocardiogr,2005,18(12):1440-1463.DOI:10.1016/j.echo.2005.10.005.
[10]
Hao G,Wang X,Chen Z,et al.Prevalence of heart failure and left
ventricular dysfunction in China:the China Hypertension
Survey,2012-2015[J].Eur J Heart
Fail,2019,21(11):1329-1337.DOI:10.1002/ejhf.1629.
[11]
中华医学会，中华医学会临床药学分会，中华医学会杂志社，等.慢性心力衰竭基层合理用药指南[J].中华全科医师杂志，2021,20(1):42-49.DOI:10.3760/cma.j.cn114798-20201118-01166.Chinese
Medical Association,Chinese Society of Clinical Pharmacy,Chinese
Medical Journals Publishing House,et al.Guideline for rational
medication of chronic heart failure in primary care[J].Chin J Gen
Pract,2021,20(1):42-49.DOI:10.3760/cma.j.cn114798-20201118-01166.
[12]
Li G,Xie J,Chen J,et al.Syndecan-4 deficiency accelerates the
transition from compensated hypertrophy to heart failure following
pressure overload[J].Cardiovasc
Pathol,2017,28:74-79.DOI:10.1016/j.carpath.2017.03.008.
[13]
Herum KM,Lunde IG,Skrbic B,et al.Syndecan-4 is a key determinant of
collagen cross-linking and passive myocardial stiffness in the
pressure-overloaded heart[J].Cardiovasc
Res,2015,106(2):217-226.DOI:10.1093/cvr/cvv002.
[14]
Bollmann M,Pinno K,Ehnold LI,et al.MMP-9 mediated Syndecan-4 shedding
correlates with osteoarthritis severity[J].Osteoarthritis
Cartilage,2021,29(2):280-289.DOI:10.1016/j.joca.2020.10.009.
[15]
Herum KM,Romaine A,Wang A,et al.Syndecan-4 protects the heart from the
profibrotic effects of thrombin-cleaved osteopontin[J/OL].J Am Heart
Assoc,2020,9(3):e013518.DOI:10.1161/JAHA.119.013518.
[16]
Jing Y,Shi J,Lu B,et al.Association of circulating cathepsin S and
cardiovascular disease among patients with type 2 diabetes:A
Cross-Sectional Community-Based Study[J].Front Endocrinol
(Lausanne),2021,12:615913.DOI:10.3389/fendo.2021.615913.
[17]
Peng K,Liu H,Yan B,et al.Inhibition of cathepsin S attenuates
myocardial ischemia/reperfusion injury by suppressing inflammation and
apoptosis[J].J Cell Physiol,2021,236(2):1309-1320.DOI:10.1002/jcp.29938.
[18]
Sugiyama A,Mitsui A,Okada M,et al.Cathepsin S degrades arresten and
canstatin in infarcted area after myocardial infarction in rats[J].J Vet
Med Sci,2019,81(4):522-531.DOI:10.1292/jvms.18-0674.
[19]
De Mingo Pulido á,de Gregorio E,Chandra S,et al.Differential role of
cathepsins S and B in hepatic APC-mediated NKT cell activation and
cytokine secretion[J].Front
Immunol,2018,9:391.DOI:10.3389/fimmu.2018.00391.
[20]
Chen H,Wang J,Xiang MX,et al.Cathepsin S-mediated fibroblast
trans-differentiation contributes to left ventricular remodelling after
myocardial infarction[J].Cardiovasc
Res,2013,100(1):84-94.DOI:10.1093/cvr/cvt158.
[21]
Nakashima M,Sakuragi S,Miyoshi T,et al.Fibrosis-4 index reflects right
ventricular function and prognosis in heart failure with preserved
ejection fraction[J].ESC Heart
Fail,2021,8(3):2240-2247.DOI:10.1002/ehf2.13317.
